Tuesday, August 21, 2012

Medical Device Reporting

Although manufacturers and importers of medical devices have been required since 1984 to report to FDA all device-related deaths, serious injuries, and certain malfunctions, numerous reports show widespread under reporting. The Safe Medical Devices Act (SMDA) was brought about in 1990 to increase the information that the FDA and manufacturers receive about serious problems involving medical devices. To implement SMDA, the FDA established the MDR regulations after several amendments.

Medical Device Reporting (MDR) is the mechanism for the FDA to receive reports from manufacturers, importers and user facilities detailing significant medical device adverse events, so they can be detected and corrected quickly. These reports can be of different types, and the user facilities (hospitals, clinics, etc) and manufacturers are required by law to report any significant adverse events or findings.

User Facilities - Should report (i) device related deaths to both FDA and the Manufacturer within 10 days; (ii) device related serious injuries to the manufacturer of the FDA (in case manufacturer is not known) within 10 days. Annual reports of deaths and serious injuries are to be filed to the FDA systematically. In addition, user facilities are to report any information that reasonably suggests that a medical device has caused or contributed to a MDR reportable event and provide all information that is reasonably known to them (no evaluation or investigation is necessary). Records related to an adverse event, whether reported or not, must be kept for two (2) years from the date of the event for FDA access.

Manufacturers - Should submit (i) 30-day reports of deaths, serious injuries or malfunctions to FDA within 30 days of being aware; (ii) baseline report to the FDA to identify and provide basic data on the device being reported (along with 30-day report); (iii) 5-day reports on events that require immediate actions/reforms to FDA within 5 work days. Following the FDA Modernization Act (FDAMA), domestic distributors are not required to file MDR reports, but must maintain complaint files. However, importers must continue to file MDR reports.

Failure to comply with the MDR regulations is a punishable criminal offense and is prohibited under the Food, Drug and Cosmetic Act FD&C Act. The MDR form or the MedWatch 3500A Form is available online and can be filed electronically. To make the process more specific, the FDA has developed a coding manual for completing FDA Form 3500A. The manual contains hundreds of codes for adverse events and will be updated as needed. Most of the MDR information other than trade secrets and financial information are available for public review. As seen, the medical device industry is highly regulated with immense emphasis given to safety and efficacy.


Monday, August 20, 2012

FDA Dispute Resolution Process (CDRH)

Regulatory science is often considered a tricky subject since it mostly involves absolutes or issues that are not distinctively black or white. In such cases, regulators make decisions based on the basis of their best judgements formed in the context of the law, implementing regulations, and previous decisions on similar cases. In some cases, regulations are not sharply drawn and can lead to more than one conclusion. These can lead to strong differences in viewpoints between the FDA's decision and the officials of the medical device industry.

Such disputes with the FDA decision can be reviewed or reconsidered by the Dispute Resolution Processes. These processes are explained in Title 21 of the Code of Federal Regulations (CFR). These processes are applicable to resolve disputes involving 510k, PMA, IDE or PDP. The primary processes are often informal involving submission of a petition requesting change or internal review. The advantages and disadvantages of these processes are seen in the image below.


Other, more formal processes can be considered. These are often time-consuming and involve hearings either in a court, or before a board of scientists, an advisory committee, or the FDA Commissioner. The advantages and disadvantages of these processes are seen in the image below.


Other specific appeal processes are available for issues involving:
*Premarket Notification
*Investigational Device Exemption
*Product Development Protocol
*Premarket Approval
*Humanitarian Device Exemption
*Post-Market Surveillance Issues
*Regulatory Compliance Issues
*Product Designation Issues and other
*Miscellaneous Issues
These appeal processes can be seen explained in the "Medical Device Appeals and Complaints" document of the FDA. (http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM094523.pdf)


Sunday, August 19, 2012

Six Sigma Process

Six Sigma Processes can be of two types depending on the stage of the business. The process used for a developed/developing business is DMAIC, while the process used for new business is DMADV. Both processes are explained in detail.

1.Six Sigma DMAIC: A systematic Six Sigma Process used to perfect business processes already in place.

D: Define M: Measure A: Analyze I: Improve C: Control

Define Phase : Define a goal for the project. This is done by identifying issues causing biggest problems and setting up requirements to define the goal-.

Measure Phase: The goals defined in the previous phase are quantified to make them real and achievable. Pertinent data is collected and stored for future reference.

Analyze Phase: Statistical tests are performed on the data collected. Other six sigma tools are also applied to collect concrete information that undoubtedly shows areas that need improvement. This step involves determining the causes of any errors, evaluation of corrective measures already in place or those that have been planned to be implemented.

Improve Phase: This step aims at implementing the solutions created based on data analysis and brainstorming. The solutions are implemented and the information is disseminated to the employees.

Control phase: This deals with any obstacles that occur and takes care of it properly and promptly.

2. Six Sigma DMADV: A systematic Six Sigma Process used to create and perfect brand new products or services.

D: Define M: Measure A: Analyze D: Design V: Verify

The first three phases, Define, Measure, and Analyze are the same as the DMAIC process.

Design Phase: This step involves design of new processes that will provide stronger support by correction or elimination of the identified error at its root to reach the goals set in the Define phase.

Verify Phase: It involves monitoring and simulation. Simulation is done before the plan or process is implemented to ensure that the error or errors have been eliminated. Once the plan is implemented, the changes are monitored to determine its effectiveness or the necessity for corrections.


Six Sigma

Six Sigma is a quality management methodology that uses different theories and tools to improve upon the processes of a certain business such that greater output is realized with less input. This results in near perfect products and services that meet and/or exceed the expectations of customers or end users, while simultaneously reducing the amount of time, money, and resources put in. In 1980's, the Motorola Corporation first created and implemented this methodology and have profited immensely since then.

Statistically, ‘Sigma’ (σ) is used to represent the statistical term ‘standard deviation’ which measures the deviations from average in a particular business process.
As the deviation from the normal increases, there is an increase in defective products or services. These ‘defects’ require resolution, which costs businesses increased time, money and resources in the long run. It is possible and practical to improve all business processes to 99.9997% perfection with the Six Sigma Methodology. The percentage of defects decreases as the number of sigma increases. The Defects Per Million Opportunities (DPMO) is only 3.4 when 6σ is employed, as opposed to 6,210 using 4σ which is the current industry standard.

Six Sigma = 3.4 DPMO, or 99.99% defect-free
Five Sigma = 233 DPMO, or 99.98% defect-free
Four Sigma = 6,210 DPMO, or 99.4% defect-free
Three Sigma = 66,807 DPMO, or 93.3% defect-free
Two Sigma = 308,538 DPMO, or 69.1% defect-free
One Sigma = 691,462 DPMO, or 30.9% defect-free

One of the most important things to note about the Six Sigma Process is that it does not rely on quick-fix programs to temporarily mask a business problem. It is a systematic methodology of hard work that is fused with a disciplined, factual, data-based and statistical problem-solving method. The amount of guesswork and product testing can be cut to a fraction, saving time and money. Therefore, it affects almost all aspects and levels of a company. Six Sigma can be applied in any field, if there is a process involved, it can be streamlined with Six Sigma.



Thursday, August 16, 2012

Steps for manufacturing successful product

According to the FD&C Act, it is required that domestic or foreign manufacturers have a quality system for the design and production of medical devices intended for commercial distribution in the United States. The regulation requires that various specifications and controls be established for devices; that devices be designed under a quality system to meet these specifications; that devices be manufactured under a quality system; that finished devices meet these specifications; that devices be correctly installed, checked and serviced; that quality data be analyzed to identify and correct quality problems; and that complaints be processed. Thus, the QS regulation helps assure that medical devices are safe and effective for their intended use. More details can be obtained from
◦ The Quality System Regulations – 21CFR 820(QSR’s)and
◦ ISO Standard 13485:2003.

The QS consists of four major actions: Design -> Manufacture -> Distribute -> Monitor performance. The FDA's QSR manual shows how any new entrepreneur can start a successful medical device company by sequentially following the steps below.

1. Obtaining information on GMP requirements;
2. Determining the appropriate quality system needed to control the design, production and distribution of the proposed device;
3. Designing products and processes;
4. Training employees;
5. Acquiring adequate facilities;
6. Purchasing and installing processing equipment;
7. Drafting the device master record;
8. Noting how to change the device master records;
9. Procuring components and materials;
10. Producing devices;
11. Labeling devices;
12. Evaluating finished devices;
13. Packaging devices;
14. Distributing devices;
15. Processing complaints and analyzing service and repair data;
16. Servicing devices;
17. Auditing and correcting deficiencies in the quality system; and,
18. Preparing for an FDA inspection.

It is to be noted how each of the steps is a comprehensive process in itself. These steps if followed according to the FDA protocols will ensure production of a successful medical device.


Combination Products

In addition to medical device regulation, the FDA also regulates food, drugs, vaccines, blood and biologics, animal and veterinary products, cosmetics, radiation emitting products and tobacco products. With respect to medical and healthcare products, the three main FDA centers for regulation are:
• CDRH: Center for Devices and Radiological Health
• CBER: Center for Biologics Evaluation and Research
• CDER: Center for Drug Evaluation and Research

In some cases, a therapeutic or diagnostic product might combine drugs, devices, and/or biological products. The FDA classifies these products as combination products. This may be,
(i) A product comprised of two or more regulated components, i.e., drug/device, biologic/device, drug/biologic, or drug/device/biologic, that are physically, chemically, or otherwise combined or mixed and produced as a single entity; or
(ii) Two or more separate products packaged together in a single package or as a unit.
Example: Drug eluting stent - It combines device and drug.

In such scenarios, it is essential to determine which FDA center gets jurisdiction of the product. It is usually determined by two main questions:
– What is the primary mode of action of the product?
– Is it a drug, biologic, or device?
If there still is any confusion, the FDA allows the manufacturer to submit a Request For Designation (RFD) form, so that the FDA can decide the primary jurisdiction for the combination product. This is to be done before filing any other device-related document to the FDA. The FDA considers the
• Primary Mode of Action
• Previous Determinations for Precedent and
• Sponsor's request with a justification
before it makes a determination.
Example: In the case of a drug eluting stent, it was classified primarily as a device, since its primary mode of action is to prevent localized vessel/flow constriction. The drug is eluted as a secondary action to prevent fibrosis and eventually re-stenosis. Hence, the product was primarily assigned to CDRH and was to consult CDER as well.


Institutional Review Board (IRB)

Institutional Review Boards (IRBs) are made up of people qualified to evaluate new and ongoing clinical trials on the basis of scientific, legal, and ethical merit. They include medical specialists as well as lay members of the community. The IRB determines whether the risks involved in a study are reasonable with respect to the potential benefits. In accordance with FDA regulations, an IRB has the authority to approve, require modifications in (to secure approval), or disapprove research. This group review serves an important role in the protection of the rights, safety and welfare of human research subjects.

FDA requires IRB registration. It is important to determine if the institution conducting the study has its own IRB. If the study is conducted at a site that does not have its own IRB, the investigators should be queried to see if they are affiliated with an institution with an IRB that would be willing to act as the IRB for that site in the study. There are also independent/contract IRBs that can be contracted with, to act as the IRB for a site. Additionally, an IRB can be established in accordance with 21 CFR 56.

The purpose of IRB review is to assure, both in advance and by periodic review, that appropriate steps are taken to protect the rights, safety and welfare of humans participating as subjects in the research. If an IRB determines that an investigation involves a significant risk device, it must notify the investigator and, if appropriate, the sponsor. The sponsor may not begin the investigation until approved by FDA.